Percutaneous aortic valve replacement

China Transcatheter Aortic Valve Replacement (TAVR) Market Report 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 28, 2021
Health, General Health, Cardiac surgery, Medical specialties, Medicine, Clinical medicine, Cardiology, Prosthetics, Aortic valve, Percutaneous aortic valve replacement, Valve replacement, Valve Corporation, Artificial heart valve, Expansion valve

The "China Transcatheter Aortic Valve Replacement (TAVR) Market Insight Report, 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China Transcatheter Aortic Valve Replacement (TAVR) Market Insight Report, 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • Surgical valve is still the basic demand of valve replacement market in China, and domestic biological surgical valve will benefit from the replacement of mechanical valve and imported valve.
  • With the listing of Edward's interventional valve SAPIEN3 in China in 2020, we believe that China's valve industry is at the development base, and the market space needs to be opened urgently.
  • In the way of interventional operation, we think that spherical expansion valve may have more advantages than self-expansion valve.

Study Data Presented at TVT on the Economics of Minimalist TAVR, PARTNER 3 Bicuspid TAVR

Retrieved on: 
Thursday, July 22, 2021
Percutaneous aortic valve replacement, Edwards Lifesciences, Army Reserve, Surgery, California, States of the United States, Economic taxonomy

The 3M-TAVR study demonstrated positive findings supporting similar clinical outcomes and substantial cost savings associated with minimalist TAVR when compared with conventional TAVR in patients at intermediate risk for surgery.

Key Points: 
  • The 3M-TAVR study demonstrated positive findings supporting similar clinical outcomes and substantial cost savings associated with minimalist TAVR when compared with conventional TAVR in patients at intermediate risk for surgery.
  • Cumulative cost differences out to 30 days post procedure were $11,305 lower in the 3M cohort compared to traditional TAVR.
  • "These data continue to build on the PARTNER 3 trial that demonstrated SAPIEN 3 TAVR to be superior to surgery for low-risk surgical patients."
  • Edwards, Edwards Lifesciences, the stylized E logo, PARTNER, PARTNER 3,SAPIEN and SAPIEN 3 are trademarks of Edwards Lifesciences Corporation.

Iona College and NewYork-Presbyterian Announce the Creation of the NewYork-Presbyterian Iona School of Health Sciences

Retrieved on: 
Thursday, July 22, 2021
Association of Catholic Colleges and Universities, Iona College, Iona, New Rochelle, New York, Presbyterianism, NewYork-Presbyterian Hospital, Bronxville, New York, New York state), Iona Preparatory School

In addition to the NewYork-Presbyterian Iona School of Health Sciences, the Iona Bronxville campus is expected to become a vibrant hub of activity hosting world-class seminars, speakers, performing arts, athletics, art exhibits, and summer camps.

Key Points: 
  • In addition to the NewYork-Presbyterian Iona School of Health Sciences, the Iona Bronxville campus is expected to become a vibrant hub of activity hosting world-class seminars, speakers, performing arts, athletics, art exhibits, and summer camps.
  • Founded in 1940 by the Congregation of Christian Brothers, Iona's 45-acre campus in northern New Rochelle is located approximately three miles from the Bronxville campus.
  • By collaborating with NewYork-Presbyterian, Iona strengthens its position as a premier institution of higher learning with a distinguished reputation in health sciences.
  • Founded in 1940, Iona College is a master's-granting private, Catholic, coeducational institution of learning in the tradition of the Edmund Rice Christian Brothers.

Establishing TAVR for the Treatment of Aortic Regurgitation(1)

Retrieved on: 
Tuesday, June 15, 2021
Anatomy, Medical specialties, Circulatory system, Cardiac surgery, Valvular heart disease, Cardiology, Aortic valve, Percutaneous aortic valve replacement, Aortic insufficiency, Regurgitation, Heart valve, Aortic valve replacement

This milestone includes patients enrolled in the multi-center prospective clinical trial, treating symptomatic, severe high surgical risk aortic regurgitation (AR) patients (The ALIGN-AR Clinical Trial).

Key Points: 
  • This milestone includes patients enrolled in the multi-center prospective clinical trial, treating symptomatic, severe high surgical risk aortic regurgitation (AR) patients (The ALIGN-AR Clinical Trial).
  • AR is a condition that occurs when a patients aortic valve does not close properly, resulting in reverse blood flow from the aorta back into the left ventricle.
  • The current treatment for high surgical risk patients who are not candidates for open-heart surgery is limited and consists of medical management.
  • JenaValve Technology, Inc., with locations in Irvine, California, Leeds, U.K., and Munich, Germany, develops and manufactures transcatheter aortic valve implantation (TAVR) systems to treat patients suffering from aortic valve disease.

Outlook on the Emerging Medical Device Technologies Global Market to 2025 - Featuring 3M, Abbott Laboratories and Allergan Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 15, 2021
Medical devices, Health, Medicine, Prosthetics, Biomedical engineering, Clinical medicine, Percutaneous aortic valve replacement, Implant, Medical device, Endoscopy, Minimally invasive procedure

that have been in use over the last 30 years for the treatment and management of various diseases.

Key Points: 
  • that have been in use over the last 30 years for the treatment and management of various diseases.
  • Emerging medical device technologies include devices and technologies (e.g., bioresorbable implants, coated implants and balloons, transcatheter heart valves (TAVR, TMVR), electrophysiology, S-ICDs, cardioMEMS, wireless monitoring, wearable devices, needle-free drug delivery, capsule endoscopes, POC tests, companion diagnostics, etc.
  • The rising demand for imaging in the diagnosis and monitoring of chronic diseases is a major contributor to the growth of the global market for emerging medical devices.
  • A shift toward minimally invasive procedures and rising adoption of hybrid operating rooms are also providing traction for the market.

Emboline Raises over $55 Million in Series D Funding for Pivotal FDA Clinical Study and Market Launch of the Emboliner™ Embolic Protection Catheter to Minimize Stroke Risk from TAVR

Retrieved on: 
Tuesday, May 25, 2021
Percutaneous aortic valve replacement, Stroke, Pivotal trial, Medicine

This investment will support a planned US-based pivotal trial for FDA approval as well as investigational studies for new indications, and manufacturing and commercial operations for the Emboliner.

Key Points: 
  • This investment will support a planned US-based pivotal trial for FDA approval as well as investigational studies for new indications, and manufacturing and commercial operations for the Emboliner.
  • The Emboliner provides embolic debris protection for all three major cerebral aortic arch vessels as well the kidneys, abdomen and lower body.
  • Unlike partial embolic protection or deflection devices, the Emboliner is designed to capture and remove all debris generated during transcatheter heart procedures.
  • Emboline, Emboliner and SafePass are trademarks of Emboline, Inc.
    View original content to download multimedia: http://www.prnewswire.com/news-releases/emboline-raises-over-55-million-...

JenaValve Technology Receives CE Mark for its Trilogy™ TAVI System for the Treatment of Aortic Regurgitation and Aortic Stenosis

Retrieved on: 
Tuesday, May 25, 2021
Medical specialties, Circulatory system, Clinical medicine, Cardiac surgery, Valvular heart disease, Cardiology, Percutaneous aortic valve replacement, Aortic valve, Aortic stenosis, Aortic insufficiency, Regurgitation, Heart valve

The Trilogy Heart Valve System is the first transfemoral device of its kind to receive CE mark approval for the treatment of both severe symptomatic aortic regurgitation and aortic stenosis.

Key Points: 
  • The Trilogy Heart Valve System is the first transfemoral device of its kind to receive CE mark approval for the treatment of both severe symptomatic aortic regurgitation and aortic stenosis.
  • With the CE Mark, the Trilogy TAVI system becomes the first TAVI system in the world approved for the treatment of aortic regurgitation in high surgical risk patients.
  • With the Trilogy valve, we now have one aortic valve that meets the clinical demands of both aortic stenosis as well as aortic regurgitation.
  • JenaValve Technology, Inc., with locations in Irvine, California, Leeds, U.K. and Munich, Germany, develops and manufactures transcatheter aortic valve implantation (TAVI) systems to treat patients suffering from aortic valve disease.

Real-World Data Confirm Excellent Results For Bicuspid Patients Treated With Edwards SAPIEN 3 TAVR

Retrieved on: 
Tuesday, May 18, 2021
Anatomy, Circulatory system, Heart, Edwards Lifesciences, Percutaneous aortic valve replacement, Aortic valve, Bicuspid aortic valve, Heart valve, Edwards, Cardiac surgery

"With bicuspid aortic valve disease as another anatomical consideration in the treatment of TAVR patients, these SAPIEN 3 data are encouraging and crucial for guiding treatment, particularly for younger patients.

Key Points: 
  • "With bicuspid aortic valve disease as another anatomical consideration in the treatment of TAVR patients, these SAPIEN 3 data are encouraging and crucial for guiding treatment, particularly for younger patients.
  • "\nThe SAPIEN 3 valve builds on Edwards\' decades of experience in the development of tissue heart valves, and the proven benefits of the Edwards SAPIEN valves.
  • These filings, along with important safety information about our products, may be found at edwards.com.\nEdwards, Edwards Lifesciences, the stylized E logo, Edwards SAPIEN, Edwards SAPIEN 3, SAPIEN, SAPIEN 3, and SAPIEN 3 Ultra are trademarks of Edwards Lifesciences Corporation.
  • This statement is made on behalf of Edwards Lifesciences Corporation and its subsidiaries.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/real-world-data-confirm-excellen...\n'

Abbott Receives CE Mark for Navitor™, the Latest-Generation Transcatheter Aortic Valve Implantation (TAVI) System to Treat Aortic Stenosis

Retrieved on: 
Monday, May 17, 2021
Medical specialties, Cardiac surgery, Clinical medicine, Medicine, Percutaneous aortic valve replacement, Aortic valve replacement, Aortic valve, Aortic stenosis, Valve replacement, Heart valve, Edwards Lifesciences, Aortic valve repair

b'ABBOTT PARK, Ill., May 17, 2021 /PRNewswire/ -- Abbott (NYSE: ABT)today announced it has received CE Mark for its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, making the minimally invasive device available for people in Europe with severe aortic stenosis who are at high or extreme surgical risk.

Key Points: 
  • b'ABBOTT PARK, Ill., May 17, 2021 /PRNewswire/ -- Abbott (NYSE: ABT)today announced it has received CE Mark for its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, making the minimally invasive device available for people in Europe with severe aortic stenosis who are at high or extreme surgical risk.
  • With the Navitor valve, the company is advancing TAVI (also referred to as TAVR, or transcatheter aortic valve replacement) therapies with innovations including a unique design to prevent blood leaking around the valve.
  • "This approval strengthens our structural heart portfolio of minimally invasive offerings by providing new options and improvements to treat a life-threatening heart condition.
  • Evaluation of patients with severe symptomatic aortic stenosis who do not undergo aortic valve replacement: the potential role of subjectively overestimated operative risk.

New Survey Identifies Opportunity to Improve Shared Decision Making Between Cardiologists and Heart Valve Disease Patients

Retrieved on: 
Friday, May 14, 2021
Cardiac surgery, Medical specialties, Clinical medicine, Medicine, Aortic valve replacement, Aortic valve, Percutaneous aortic valve replacement, Aortic stenosis, Valve replacement, Valvular heart disease, Aortic valve repair, Mitral valve replacement

Currently, treatment options for AS include transcatheter aortic valve replacement (TAVR), a minimally invasive procedure, or a surgical aortic valve replacement (SAVR), also known as open heart surgery.

Key Points: 
  • Currently, treatment options for AS include transcatheter aortic valve replacement (TAVR), a minimally invasive procedure, or a surgical aortic valve replacement (SAVR), also known as open heart surgery.
  • However, more than half of cardiologists surveyed (53%) feel that their symptomatic severe AS patients are not as informed as they should be about their treatment options.\nThe findings indicate physicians recognize the importance of shared decision making to achieve individualized care for heart valve disease patients.
  • More than 3,400 responses were received from heart valve patients and caregivers.
  • Of the respondents, 94% identified as heart valve patients, 53% identified as aortic stenosis patients.\n'